Form 4: Vanda Pharmaceuticals SVP, Chief Marketing Officer, Joakim Wijkstrom, Reports Stock Sales to Cover Tax Obligations

Joakim Wijkstrom, SVP, Chief Marketing Officer of Vanda Pharmaceuticals, reports selling shares of common stock to cover tax obligations related to vested RSUs.

Summary

• On March 4, 2024, Joakim Wijkstrom, SVP, Chief Marketing Officer of Vanda Pharmaceuticals, sold 7,498 shares of common stock at a weighted average price of $4.4133.
• These shares were sold in multiple transactions with prices ranging from $4.38 to $4.4402.
• Following this transaction, Wijkstrom directly owns 139,018 shares of Vanda Pharmaceuticals.
• On March 5, 2024, Wijkstrom sold 9,229 shares of common stock at a weighted average price of $4.2074.
• These shares were sold in multiple transactions with prices ranging from $4.2027 to $4.225.
• Following this transaction, Wijkstrom directly owns 129,789 shares of Vanda Pharmaceuticals.
• The sales were executed to satisfy tax obligations related to the acquisition of shares from the settlement of vested Restricted Stock Units (RSUs) under the 'same day sale' provisions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales to cover tax obligations, a routine transaction.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates